Marker Therapeutics: 78% objective response in APOLLO study; raises $16.1M in private placement

Marker Therapeutics, Inc.

Phase 1 APOLLO: 78% of patients (7/9) achieved objective response; 44.4% complete response at first assessment.
MT-601 well tolerated; no ICANS observed, one Grade 1 CRS; no dose-limiting toxicities.
Private placement raises $16.1M gross proceeds; 5,031,250 shares at $3.20 with warrants at $4.03.
Proceeds to support clinical advancement of MT-601 in relapsed lymphoma after CAR-T failure.
New and existing investors: Blue Owl, NEA, and Aisling Capital participated in the financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.